News - OBI Pharma 台灣浩鼎

2025.Sep.03

Corporate

OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC

2025.Sep.01

Corporate

OBI Pharma, Inc. Announces Board Resolution for Capital Reduction to Offset Accumulated Losses and Holds Material Information Press Conference

2025.Aug.31

Corporate

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

2025.Jul.22

Corporate

OBI Pharma Showcases Innovative Pipeline, Platforms, and Technologies at BIO Asia–Taiwan 2025
GlycOBI® and HYPrOBI™ Drive the Advancement of Bispecific, Dual-Payload ADCs

2025.Jun.27

Corporate

Innovation in Action: OBI Pharma Sharpens Focus on ADC Products, Platforms, and Out-Licensing
Integrating Product and Platform Capabilities to Drive Global Collaboration

2025.Jun.10

Corporate

OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit

2025.Jun.06

Corporate

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

2025.May.01

Corporate

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

2025.Apr.29

Corporate

OBI Pharma Unveils New ThiOBI® and HYPrOBI™ Platforms
Showcasing Strong ADC Development Capabilities and Captivating Attention at AACR

2025.Apr.23

Corporate

OBI-822 Completes Second Interim Analysis of Phase III Trial
OBI Announces Trial Termination, Refocuses Resources on ADC Development

Announcements

Latest announcements

Events

Latest events